Long-term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

被引：0
|
作者：
Giovannoni, G. [1 ]
Comi, G. [2 ,3 ]
Rammohan, K. [4 ]
Rieckmann, P. [5 ,6 ]
Vermersch, P. [7 ]
Dangond, F. [8 ]
Keller, B. [9 ]
Jack, D. [9 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[2] Univ Vita Salute San Raffaele, Dept Neurol, Osped San Raffaele, Milan, Italy
[3] Univ Vita Salute San Raffaele, Inst Expt Neurol, Osped San Raffaele, Milan, Italy
[4] Univ Miami, Sch Med, MS Res Ctr, Miami, FL USA
[5] Med Pk Loipl, Ctr Clin Neuroplast, Erlangen, Germany
[6] Univ Erlangen Nurnberg, Erlangen, Germany
[7] Univ Lille, INSERM, CHU Lille, FHU Imminent,U1172, Lille, France
[8] EMD Serono Res & Dev Inst Inc, Billerica, MA USA
[9] Merck KGaA, Darmstadt, Germany
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR3084
引用
收藏
页码：468 / 468
页数：1
相关论文
共 50 条
  • [31] Benefits of cladribine tablets on the proportion of patients with multiple sclerosis free from clinical and radiological indicators of disease activity in the CLARITY EXTENSION study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rieckmann, P.
    Rammohan, K.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Adeniji, A.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 300 - 301
  • [32] Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion
    Meuth, Sven G.
    Bayas, Antonios
    Kallmann, Boris
    Kleinschnitz, Christoph
    Linker, Ralf
    Rieckmann, Peter
    Maeurer, Mathias
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (16) : 1965 - 1969
  • [33] Evaluation of Disability Improvement in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Cladribine Tablets as Measured by the Expanded Disability Status Scale Score
    Sormani, Maria Pia
    Signori, Alessio
    Giovannoni, Gavin
    Alexandri, Nektaria
    NEUROLOGY, 2020, 94 (15)
  • [34] Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
    Helen Bell Gorrod
    Nicholas R. Latimer
    Doris Damian
    Robert Hettle
    Gerard T. Harty
    Schiffon L. Wong
    Advances in Therapy, 2020, 37 : 225 - 239
  • [35] Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
    Gorrod, Helen Bell
    Latimer, Nicholas R.
    Damian, Doris
    Hettle, Robert
    Harty, Gerard T.
    Wong, Schiffon L.
    ADVANCES IN THERAPY, 2020, 37 (01) : 225 - 239
  • [36] Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study
    Giovannoni, Gavin
    Boyko, Alexey
    Correale, Jorge
    Edan, Gilles
    Freedman, Mark S.
    Montalban, Xavier
    Rammohan, Kottil
    Stefoski, Dusan
    Yamout, Bassem
    Leist, Thomas
    Aydemir, Aida
    Borsi, Laszlo
    di Cantogno, Elisabetta Verdun
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (06) : 719 - 730
  • [37] Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
    Meuth, Sven G.
    Bayas, Antonios
    Kallmann, Boris
    Linker, Ralf
    Rieckmann, Peter
    Wattjes, Mike P.
    Maeurer, Mathias
    Kleinschnitz, Christoph
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1503 - 1510
  • [38] CLARITY extension: sustained efficacy in relapsing remitting multiple sclerosis following switch from cladribine tablets to placebo in patients with high disease activity at baseline
    Vermersch, P.
    Giovannoni, G.
    Soelberg-Sorensen, P.
    Keller, B.
    Jack, D.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 867 - 867
  • [39] Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis
    Giovannoni, Gavin
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Hamlett, Anthony
    Viglietta, Vissia
    Greenberg, Steven
    LANCET NEUROLOGY, 2011, 10 (04): : 329 - 337
  • [40] Benefits of cladribine tablets on relapse rates and disability progression in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies
    Giovannoni, G.
    Montalban, X.
    Hicking, C.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 305 - 305
12345